TY - JOUR
T1 - Recent progress in cell therapy for basal ganglia disorders with emphasis on menstrual blood transplantation in stroke
AU - Rodrigues, Maria Carolina Oliveira
AU - Voltarelli, Julio
AU - Sanberg, Paul R.
AU - Allickson, Julie G.
AU - Kuzmin-Nichols, Nicole
AU - Garbuzova-Davis, Svitlana
AU - Borlongan, Cesar V.
N1 - Funding Information:
CVB and SGD are funded by James and Esther King Biomedical Research Program . CVB and PRS have a patent application on menstrual blood stem cells for stroke therapy. CVB, PRS, and SGD are consultants of Saneron-CCEL Therapeutics Inc. The authors express their gratitude to Ms. Cate Bae for technical assistance in the preparation of this manuscript.
PY - 2012/1
Y1 - 2012/1
N2 - Cerebrovascular diseases are the third leading cause of death and the primary cause of long-term disability in the United States. The only approved therapy for stroke is tPA, strongly limited by the short therapeutic window and hemorrhagic complications, therefore excluding most patients from its benefits. Parkinson's and Huntington's disease are the other two most studied basal ganglia diseases and, as stroke, have very limited treatment options. Inflammation is a key feature in central nervous system disorders and it plays a dual role, either improving injury in early phases or impairing neural survival at later stages. Stem cells can be opportunely used to modulate inflammation, abrogate cell death and, therefore, preserve neural function. We here discuss the role of stem cells as restorative treatments for basal ganglia disorders, including Parkinson's disease, Huntington's disease and stroke, with special emphasis to the recently investigated menstrual blood stem cells. We highlight the availability, proliferative capacity, pluripotentiality and angiogenic features of these cells and explore their present and future experimental and clinical applications.
AB - Cerebrovascular diseases are the third leading cause of death and the primary cause of long-term disability in the United States. The only approved therapy for stroke is tPA, strongly limited by the short therapeutic window and hemorrhagic complications, therefore excluding most patients from its benefits. Parkinson's and Huntington's disease are the other two most studied basal ganglia diseases and, as stroke, have very limited treatment options. Inflammation is a key feature in central nervous system disorders and it plays a dual role, either improving injury in early phases or impairing neural survival at later stages. Stem cells can be opportunely used to modulate inflammation, abrogate cell death and, therefore, preserve neural function. We here discuss the role of stem cells as restorative treatments for basal ganglia disorders, including Parkinson's disease, Huntington's disease and stroke, with special emphasis to the recently investigated menstrual blood stem cells. We highlight the availability, proliferative capacity, pluripotentiality and angiogenic features of these cells and explore their present and future experimental and clinical applications.
KW - Basal ganglia disorders
KW - Cell-based therapy
KW - Endometrium-derived stem cells
KW - Huntington's disease
KW - Menstrual blood stem cells
KW - Parkinson's disease
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=82855175251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82855175251&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2011.05.010
DO - 10.1016/j.neubiorev.2011.05.010
M3 - Review article
C2 - 21645544
AN - SCOPUS:82855175251
SN - 0149-7634
VL - 36
SP - 177
EP - 190
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
IS - 1
ER -